Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Trimel Pharmaceuticals Corp

+ Add to Watchlist

TRLPF:US

0.5587 USD 0.0093 1.64%

As of 20:10:04 ET on 01/30/2015.

Snapshot for Trimel Pharmaceuticals Corp (TRLPF)

Open: 0.5587 Day's Range: 0.5587 - 0.5587 Volume: 4,000
Previous Close: 0.5680 52wk Range: 0.2950 - 0.8500 1-Yr Rtn: -19.61%

Stock Chart for TRLPF

No chart data available.
  • TRLPF:US 0.5587
  • 1D
  • 1M
  • 1Y
0.5680
Interactive TRLPF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TRLPF

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.0900
Est. PEG Ratio -
Market Cap (M USD) 112.23
Shares Outstanding (M) 200.87
30 Day Average Volume 1,571
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TRLPF

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for TRLPF

Trimel Pharmaceuticals Corp. is a pharmaceutical development company. The Company's primary objective is to exploit Trimel's drug-delivery technology portfolio and to target unmet medical needs in underserved disease states. Trimel's term objectives include the development of products for the treatment of male hypogonadism, female sexual dysfunction, and Parkinson's disease.

Tom RossiPresident/CEOKenneth G HowlingChief Financial Officer
Nathan John BrysonVP:Chief Scientific Officer
More Company Profile & Key Executives for TRLPF

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil